These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28332899)

  • 21. Adapting the Abbreviated Impactor Measurement (AIM) concept to make appropriate inhaler aerosol measurements to compare with clinical data: a scoping study with the "Alberta" idealized throat (AIT) inlet.
    Mitchell J; Copley M; Sizer Y; Russell T; Solomon D
    J Aerosol Med Pulm Drug Deliv; 2012 Aug; 25(4):188-97. PubMed ID: 22857270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer.
    Waldrep JC; Berlinski A; Dhand R
    J Aerosol Med; 2007; 20(3):310-9. PubMed ID: 17894537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro, ex vivo, in vivo veritas.
    Borgström L
    Allergy; 1999; 54 Suppl 49():88-92. PubMed ID: 10422754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delivered Lung Dose and Aerodynamic Particle Size Distribution of Salbutamol Pressurized Metered Dose Inhaler After Living Under Patients' Realistic Retention Environments.
    Ammari WG; Khalil Mohammad M; Tayyem RF; Martin GP; Royall PG
    J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):386-395. PubMed ID: 31199708
    [No Abstract]   [Full Text] [Related]  

  • 25. In-vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler.
    Tarsin W; Assi KH; Chrystyn H
    J Aerosol Med; 2004; 17(1):25-32. PubMed ID: 15120010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer.
    Mitchell JP; Nagel MW; Wiersema KJ; Doyle CC
    AAPS PharmSciTech; 2003 Oct; 4(4):E54. PubMed ID: 15198549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aerosol characteristics of admixture of budesonide inhalation suspension with a beta2-agonist, procaterol.
    Itazawa T; Adachi Y; Ito Y; Higuchi O; Mochizuki H; Shimojo N; Inoue T
    Allergol Int; 2013 Mar; 62(1):131-5. PubMed ID: 23348859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Development and Validation of an In Vitro Airway Model to Assess Realistic Airway Deposition and Drug Permeation Behavior of Orally Inhaled Products Across Synthetic Membranes.
    Huynh BK; Traini D; Farkas DR; Longest PW; Hindle M; Young PM
    J Aerosol Med Pulm Drug Deliv; 2018 Apr; 31(2):103-108. PubMed ID: 28880765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of patients' real-world post-dispensing use and storage environments of tiotropium bromide Respimat® soft mist inhaler on its in vitro dose delivery and lung deposition.
    Ammari WG; Khalil Mohammad M; Tayyem RF
    Pulm Pharmacol Ther; 2019 Oct; 58():101829. PubMed ID: 31352077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breath-synchronized plume-control inhaler for pulmonary delivery of fluticasone propionate.
    Shrewsbury SB; Armer TA; Newman SP; Pitcairn G
    Int J Pharm; 2008 May; 356(1-2):137-43. PubMed ID: 18289809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Air classifier technology (ACT) in dry powder inhalation Part 3. Design and development of an air classifier family for the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):72-80. PubMed ID: 16442248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aerosol delivery of nebulised budesonide in young children with asthma.
    Schueepp KG; Devadason SG; Roller C; Minocchieri S; Moeller A; Hamacher J; Wildhaber JH
    Respir Med; 2009 Nov; 103(11):1738-45. PubMed ID: 19540100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
    Son YJ; Worth Longest P; Hindle M
    Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimized aerosol delivery to a mechanically ventilated rodent.
    MacLoughlin RJ; Higgins BD; Laffey JG; O'Brien T
    J Aerosol Med Pulm Drug Deliv; 2009 Dec; 22(4):323-32. PubMed ID: 19415985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler.
    Biswas R; Hanania NA; Sabharwal A
    J Aerosol Med Pulm Drug Deliv; 2017 Aug; 30(4):256-266. PubMed ID: 28157430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discriminating Ability of Abbreviated Impactor Measurement Approach (AIM) to Detect Changes in Mass Median Aerodynamic Diameter (MMAD) of an Albuterol/Salbutamol pMDI Aerosol.
    David Christopher J; Patel RB; Mitchell JP; Tougas TP; Goodey AP; Quiroz J; Andersson PU; Lyapustina S
    AAPS PharmSciTech; 2017 Nov; 18(8):3296-3306. PubMed ID: 28589305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scintigraphic evaluation of lung deposition with a novel inhaler device.
    Newman SP; Hirst PH; Pitcairn GR
    Curr Opin Pulm Med; 2001 Apr; 7 Suppl 1():S12-4. PubMed ID: 11385810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computational Fluid Dynamics (CFD) Guided Spray Drying Recommendations for Improved Aerosol Performance of a Small-Particle Antibiotic Formulation.
    Longest W; Hassan A; Farkas D; Hindle M
    Pharm Res; 2022 Feb; 39(2):295-316. PubMed ID: 35147870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of particle deposition density of dry powders on the results produced by an in vitro test system simulating dissolution- and absorption rates in the lungs.
    Malmlöf M; Nowenwik M; Meelich K; Rådberg I; Selg E; Burns J; Mascher H; Gerde P
    Eur J Pharm Biopharm; 2019 Jun; 139():213-223. PubMed ID: 30862480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.